Meeting
2020 Gastrointestinal Cancers Symposium
Prognostic and predictive value of circulating tumour DNA (ctDNA) by amplicon-based next generation sequencing (NGS) of advanced pancreatic cancer (APC) in a phase I trial of oxaliplatin capecitabine and irinotecan (OXIRI) triplet chemotherapy.
Authors
Amanda Oon Lim Seet
National Cancer Center, Singapore, Singapore
Amanda Oon Lim Seet , Su Pin Choo , David Wai-Meng Tai , Justina Yick Ching Lam , Tira Jing Ying Tan , Daniel Shao-Weng Tan , Aaron C. Tan , Yvonne Chang , Balram Chowbay , Matthew C.H. Ng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02368860
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 730)
Abstract #
730
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Oxaliplatin (OX), chronomodulated capecitabine, and UGT1A1 genotype-directed dosing of irinotecan (IR) triplet chemotherapy (OXIRI) in patients (pts) with advanced pancreatic cancer (APC).
First Author: Amanda Oon Lim Seet
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance.
First Author: Tom Zhang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.
First Author: Liangjun Zhu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
First Author: Paul Eliezer Oberstein